SEARCH:   Advanced

Blood, 1 July 2006, Vol. 108, No. 1, pp. 311-318. Prepublished online as a Blood First Edition Paper on March 16, 2006; DOI 10.1182/blood-2005-11-4742. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-11-4742v1 108/1/311    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Roberts, R. A. Articles by Rimsza, L. M. Search for Related Content PubMed PubMed Citation Articles by Roberts, R. A. Articles by Rimsza, L. M. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival Robin A. Roberts, George Wright, Andreas R. Rosenwald, Marina A. Jaramillo, Thomas M. Grogan, Thomas P. Miller, Yvette Frutiger, Wing C. Chan, Randy D. Gascoyne, German Ott, H. Konrad Muller-Hermelink, Louis M. Staudt, and Lisa M. Rimsza From the Department of Pathology, University of Arizona, Tucson, AZ; the Arizona Cancer Center, University of Arizona, Tucson, AZ; the Biometric Research Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; the Metabolism Branch, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD; the Department of Pathology, University of Wuerzburg, Wuerzburg, Germany; the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; and the British Columbia Cancer Center, Vancouver, BC, Canada. Loss of major histocompatibility class II (MHC II) expression in diffuse large B-cell lymphoma (DLBCL) correlates with worse outcome, possibly from decreased immunosurveillance. Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of DLBCL which reportedly has frequent loss of MHC II proteins; however, PM-BCL has better survival than DLBCL. To investigate this paradox, we used geneexpression profiling (GEP) data and immunohistochemistry to study expression of MHC II and its regulatory genes and to determine their relationship to PMBCL survival. We found that GEP levels correlated between MHC II genes and the transcriptional regulator MHC2TA but not other adjacent genes, implying that transcriptional regulation of MHC II in PMBCL was intact and that MHC II gene deletion was unlikely. MHC II average expression was lower than in certain subtypes of DLBCL; however, only 12% had complete loss of MHC II expression. Poor patient survival in PMBCL correlated with incremental decreases in MHC II expression. Although overall survival was better, survival of the lowest 10% of MHC II expressers was similarly poor in DLBCL and PMBCL. MHC II expression may define a therapeutic target in both these diseases. (Blood. 2006;108:311-318) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P. W.M. Johnson and A. J. Davies Primary Mediastinal B-Cell Lymphoma Hematology, January 1, 2008; 2008(1): 349 - 358. [Abstract] [Full Text] [PDF] A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al. HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3101 - 3108. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020